News >

EU Panel Backs Polatuzumab Vedotin Approval for DLBCL

Jason M. Broderick @jasoncology
Published: Friday, Nov 15, 2019

Levi Garraway, MD, PhD

Levi Garraway, MD, PhD
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the antibody-drug conjugate (ADC) polatuzumab vedotin (Polivy) for use in combination with bendamustine and rituximab (BR) for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for a hematopoietic stem cell transplant.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication